Published on
March 30, 2020
- 12:00 GMT
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have opted to enroll in the ENDYMION open-label extension study …
Distribution channels:
Media, Advertising & PR, Technology
...
